Jiří Zurek1, Michal Fedora. 1. Department of Anesthesia and Intensive Care, University Children's Hospital, Brno, Czech Republic. jzurek@fnbrno.cz
Abstract
BACKGROUNDS: Glial fibrillary acidic protein (GFAP) is a monomeric intermediate filament protein found in the astroglial cytoskeleton and is not found outside the central nervous system. It is a brain-specific protein that is released after traumatic brain injury (TBI). METHODS: This prospective study enrolled 59 children who had TBI, as verified by computed tomography. Daily GFAP measurement began at admission (<12 hours after trauma) and continued for 6 days. Blood samples were analyzed for GFAP by enzyme-linked immunosorbent assay. Outcome was assessed using the Glasgow Outcome Scale (GOS) at 6 months after injury. RESULTS: The median serum levels of GFAP at admission were 7.47 ng/mL in patients who died, compared with 0.12 ng/mL in patients who survived (p=0.002). GFAP levels were significantly higher in patients who had a poor outcome 6 months after injury than in those who were alive or had good outcome (p<0.001). The area under the receiver operating characteristic curve for GFAP was 0.833 for day 0 and 0.884 for day 2. CONCLUSIONS: These results suggest that determination of serum levels of GFAP may add to the clinical assessment of the primary damage and prediction of outcome after severe TBI.
BACKGROUNDS: Glial fibrillary acidic protein (GFAP) is a monomeric intermediate filament protein found in the astroglial cytoskeleton and is not found outside the central nervous system. It is a brain-specific protein that is released after traumatic brain injury (TBI). METHODS: This prospective study enrolled 59 children who had TBI, as verified by computed tomography. Daily GFAP measurement began at admission (<12 hours after trauma) and continued for 6 days. Blood samples were analyzed for GFAP by enzyme-linked immunosorbent assay. Outcome was assessed using the Glasgow Outcome Scale (GOS) at 6 months after injury. RESULTS: The median serum levels of GFAP at admission were 7.47 ng/mL in patients who died, compared with 0.12 ng/mL in patients who survived (p=0.002). GFAP levels were significantly higher in patients who had a poor outcome 6 months after injury than in those who were alive or had good outcome (p<0.001). The area under the receiver operating characteristic curve for GFAP was 0.833 for day 0 and 0.884 for day 2. CONCLUSIONS: These results suggest that determination of serum levels of GFAP may add to the clinical assessment of the primary damage and prediction of outcome after severe TBI.
Authors: Heba Allah Abd El Rahman; Mohamed Salama; Seham A Gad El-Hak; Mona A El-Harouny; Passent ElKafrawy; Mohamed B Abou-Donia Journal: Neurotox Res Date: 2017-09-05 Impact factor: 3.911
Authors: Tyler A Kokjohn; Chera L Maarouf; Ian D Daugs; Jesse M Hunter; Charisse M Whiteside; Michael Malek-Ahmadi; Emma Rodriguez; Walter Kalback; Sandra A Jacobson; Marwan N Sabbagh; Thomas G Beach; Alex E Roher Journal: J Neurotrauma Date: 2013-06-01 Impact factor: 5.269
Authors: Hani Daoud; Ibrahim Alharfi; Ibrahim Alhelali; Tanya Charyk Stewart; Hadiah Qasem; Douglas D Fraser Journal: Neurocrit Care Date: 2014-06 Impact factor: 3.210
Authors: Teemu M Luoto; Rahul Raj; Jussi P Posti; Andrew J Gardner; William J Panenka; Grant L Iverson Journal: Front Neurol Date: 2017-12-04 Impact factor: 4.003
Authors: Eric Peter Thelin; Frederick Adam Zeiler; Ari Ercole; Stefania Mondello; András Büki; Bo-Michael Bellander; Adel Helmy; David K Menon; David W Nelson Journal: Front Neurol Date: 2017-07-03 Impact factor: 4.003